Association between CD16++ monocytes in peripheral blood and clinical features and short-term therapeutic effects of polycystic ovary syndrome
Abstract
OBJECTIVE: To evaluate the association between CD16++ monocytes in peripheral blood and the clinical features and short-term therapeutic effects of polycystic ovary syndrome (PCOS).
METHODS: This prospective cross-sectional study included women diagnosed with PCOS at a University Hospital in Shanghai, China, between June 4 and November 28, 2016. Patients received Diane-35, metformin, or both combined for 3 months. We collected anthropometric measures and used flow cytometry to detect CD16++ monocytes.
RESULTS: The final analysis included 70 patients: 18 in the Diane-35 group, 30 in the metformin group, and 22 in the Diane-35 plus metformin group. The control group comprised 60 women without PCOS. The proportion of CD16++ monocytes was significantly higher in patients with PCOS than in those with no PCOS (16.05% vs 10.73%; P=0.001). The proportion differed significantly between patients with and those without hyperandrogenism (13.12% vs 17.30%; P=0.002) and showed moderate accuracy in diagnosing hyperandrogenism before treatment. We noted a decrease in monocytes post-treatment in patients given metformin and Diane-35 plus metformin.
CONCLUSIONS: The proportion of CD16++ monocytes was most significantly associated with hyperandrogenism before treatment. Our findings suggest that the proportion of CD16++ monocytes in peripheral blood might be related to the inflammatory condition of PCOS.
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 70 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.